| INVITED RESEARCH HIGHLIGHT |
|
| Year : 2015 | Volume
: 17
| Issue : 6 | Page : 878-881 |
|
|
Testosterone replacement therapy and the risk of prostate cancer
Daniel Warburton1, Christopher Hobaugh1, Grace Wang1, Haocheng Lin1, Run Wang2
1 Division of Urology, University of Texas Medical School at Houston, Department of Urology, Houston, Texas, USA
2 Division of Urology, University of Texas Medical School at Houston, Department of Urology; University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Correspondence Address:
Run Wang
Division of Urology, University of Texas Medical School at Houston, Department of Urology; University of Texas MD Anderson Cancer Center, Houston, Texas 77030
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1008-682X.150841
|
|
|
Understanding the role of testosterone replacement therapy (TRT) in the development and progression of prostate cancer is an important concept in treating patients with symptoms of hypogonadism. This article revealed a small number of mostly retrospective, observational studies describing the use of TRT in the general population, in men with prostatic intraepithelial neoplasia (PIN), in men with a history of treated prostate cancer, and in men on active surveillance for prostate cancer. The current literature does not report a statistically significant increase in the development or progression of prostate cancer in men receiving testosterone replacement for symptomatic hypogonadism, and the prostate saturation theory provides a model explaining the basis for these results. The use of TRT in men with a history of prostate cancer is considered experimental, but future results from randomized controlled trials could lead to a change in our current treatment approach. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
